Shares of I-Mab (IMAB) are rising over 6% in pre-market today, after the company announced that the U.S. FDA has cleared the company's Investigational New Drug application or IND to initiate clinical study for TJM2 to treat cytokine release syndrome or CRS associated with severe illness caused by the coronavirus disease 2019 (COVID-19).
from RTT - Before the Bell https://ift.tt/2R9v69L
via IFTTT
No comments:
Post a Comment